Home › All Companies › TPST

Tempest Therapeutics, Inc. (TPST)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-03-25

Key Insights

  • Matthew Angel, the CEO and President of Tempest Therapeutics, Inc., has acquired 231,482 shares of the company's common stock at a price of $2.16 per share, indicating his confidence in the company's future.
  • Angel owns a significant stake of 4,837,070 direct shares in the company, representing his substantial investment and alignment with shareholder interests.
  • The filing also discloses that Angel indirectly owns shares through his position as the CEO and chairman of the board of Factor Bioscience Inc., which holds an additional 231,482 shares.
Sentiment: Positive Significance: 7/10
View Original Filing →

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.